A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles

Sara Capolla, Nelly Mezzaroba, Sonia Zorzet, Claudio Tripodo, Ramiro Mendoza-Maldonado, Marilena Granzotto, Francesca Vita, Ruben Spretz, Gustavo Larsen, Sandra Noriega, Eduardo Mansilla, Michele Dal Bo, Valter Gattei, Gabriele Pozzato, Luis Núñez, Paolo Macor

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegradable polymeric nanoparticles coated with an anti-CD20 antibody.We first demonstrated the ability of the nanoparticles to target and internalize in tumor B-cells. Moreover, these nanoparticles could kill not only p53-mutated/deleted leukemia cells expressing a low amount of CD20, but also circulating primary cells isolated from chronic lymphocytic leukemia patients. The safety of these nanoparticles was also demonstrated in healthy mice, and their therapeutic effects were shown in a new model of aggressive leukemia. These results showed that anti-CD20 nanoparticles containing hydroxychloroquine and chlorambucil can be effective in controlling aggressive leukemia and provided a rationale for adopting this approach for the treatment of other B-cell disorders. [Figure not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)537-548
Number of pages12
JournalNano Research
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Hydroxychloroquine
Chlorambucil
Nanoparticles
Cells
Cytotoxicity
Antibodies
Tumors
Pharmaceutical Preparations

Keywords

  • chronic lymphocytic leukemia
  • immune targeted nanoparticles
  • treatment
  • xenograft model

ASJC Scopus subject areas

  • Materials Science(all)
  • Electrical and Electronic Engineering

Cite this

Capolla, S., Mezzaroba, N., Zorzet, S., Tripodo, C., Mendoza-Maldonado, R., Granzotto, M., ... Macor, P. (2016). A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. Nano Research, 9(2), 537-548. https://doi.org/10.1007/s12274-015-0935-3

A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. / Capolla, Sara; Mezzaroba, Nelly; Zorzet, Sonia; Tripodo, Claudio; Mendoza-Maldonado, Ramiro; Granzotto, Marilena; Vita, Francesca; Spretz, Ruben; Larsen, Gustavo; Noriega, Sandra; Mansilla, Eduardo; Dal Bo, Michele; Gattei, Valter; Pozzato, Gabriele; Núñez, Luis; Macor, Paolo.

In: Nano Research, Vol. 9, No. 2, 01.02.2016, p. 537-548.

Research output: Contribution to journalArticle

Capolla, S, Mezzaroba, N, Zorzet, S, Tripodo, C, Mendoza-Maldonado, R, Granzotto, M, Vita, F, Spretz, R, Larsen, G, Noriega, S, Mansilla, E, Dal Bo, M, Gattei, V, Pozzato, G, Núñez, L & Macor, P 2016, 'A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles', Nano Research, vol. 9, no. 2, pp. 537-548. https://doi.org/10.1007/s12274-015-0935-3
Capolla S, Mezzaroba N, Zorzet S, Tripodo C, Mendoza-Maldonado R, Granzotto M et al. A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. Nano Research. 2016 Feb 1;9(2):537-548. https://doi.org/10.1007/s12274-015-0935-3
Capolla, Sara ; Mezzaroba, Nelly ; Zorzet, Sonia ; Tripodo, Claudio ; Mendoza-Maldonado, Ramiro ; Granzotto, Marilena ; Vita, Francesca ; Spretz, Ruben ; Larsen, Gustavo ; Noriega, Sandra ; Mansilla, Eduardo ; Dal Bo, Michele ; Gattei, Valter ; Pozzato, Gabriele ; Núñez, Luis ; Macor, Paolo. / A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. In: Nano Research. 2016 ; Vol. 9, No. 2. pp. 537-548.
@article{6e634c8ab9964725a3f425850ffbfc88,
title = "A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles",
abstract = "Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegradable polymeric nanoparticles coated with an anti-CD20 antibody.We first demonstrated the ability of the nanoparticles to target and internalize in tumor B-cells. Moreover, these nanoparticles could kill not only p53-mutated/deleted leukemia cells expressing a low amount of CD20, but also circulating primary cells isolated from chronic lymphocytic leukemia patients. The safety of these nanoparticles was also demonstrated in healthy mice, and their therapeutic effects were shown in a new model of aggressive leukemia. These results showed that anti-CD20 nanoparticles containing hydroxychloroquine and chlorambucil can be effective in controlling aggressive leukemia and provided a rationale for adopting this approach for the treatment of other B-cell disorders. [Figure not available: see fulltext.]",
keywords = "chronic lymphocytic leukemia, immune targeted nanoparticles, treatment, xenograft model",
author = "Sara Capolla and Nelly Mezzaroba and Sonia Zorzet and Claudio Tripodo and Ramiro Mendoza-Maldonado and Marilena Granzotto and Francesca Vita and Ruben Spretz and Gustavo Larsen and Sandra Noriega and Eduardo Mansilla and {Dal Bo}, Michele and Valter Gattei and Gabriele Pozzato and Luis N{\'u}{\~n}ez and Paolo Macor",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s12274-015-0935-3",
language = "English (US)",
volume = "9",
pages = "537--548",
journal = "Nano Research",
issn = "1998-0124",
publisher = "Press of Tsinghua University",
number = "2",

}

TY - JOUR

T1 - A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles

AU - Capolla, Sara

AU - Mezzaroba, Nelly

AU - Zorzet, Sonia

AU - Tripodo, Claudio

AU - Mendoza-Maldonado, Ramiro

AU - Granzotto, Marilena

AU - Vita, Francesca

AU - Spretz, Ruben

AU - Larsen, Gustavo

AU - Noriega, Sandra

AU - Mansilla, Eduardo

AU - Dal Bo, Michele

AU - Gattei, Valter

AU - Pozzato, Gabriele

AU - Núñez, Luis

AU - Macor, Paolo

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegradable polymeric nanoparticles coated with an anti-CD20 antibody.We first demonstrated the ability of the nanoparticles to target and internalize in tumor B-cells. Moreover, these nanoparticles could kill not only p53-mutated/deleted leukemia cells expressing a low amount of CD20, but also circulating primary cells isolated from chronic lymphocytic leukemia patients. The safety of these nanoparticles was also demonstrated in healthy mice, and their therapeutic effects were shown in a new model of aggressive leukemia. These results showed that anti-CD20 nanoparticles containing hydroxychloroquine and chlorambucil can be effective in controlling aggressive leukemia and provided a rationale for adopting this approach for the treatment of other B-cell disorders. [Figure not available: see fulltext.]

AB - Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegradable polymeric nanoparticles coated with an anti-CD20 antibody.We first demonstrated the ability of the nanoparticles to target and internalize in tumor B-cells. Moreover, these nanoparticles could kill not only p53-mutated/deleted leukemia cells expressing a low amount of CD20, but also circulating primary cells isolated from chronic lymphocytic leukemia patients. The safety of these nanoparticles was also demonstrated in healthy mice, and their therapeutic effects were shown in a new model of aggressive leukemia. These results showed that anti-CD20 nanoparticles containing hydroxychloroquine and chlorambucil can be effective in controlling aggressive leukemia and provided a rationale for adopting this approach for the treatment of other B-cell disorders. [Figure not available: see fulltext.]

KW - chronic lymphocytic leukemia

KW - immune targeted nanoparticles

KW - treatment

KW - xenograft model

UR - http://www.scopus.com/inward/record.url?scp=84958102109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958102109&partnerID=8YFLogxK

U2 - 10.1007/s12274-015-0935-3

DO - 10.1007/s12274-015-0935-3

M3 - Article

VL - 9

SP - 537

EP - 548

JO - Nano Research

JF - Nano Research

SN - 1998-0124

IS - 2

ER -